Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Diehl, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diehl, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 9:S67-S71, 1998
© 1998 European Society for Medical Oncology

Reviews

BEACOPP: A new regimen for advanced Hodgkin's disease

V. Diehl, J. Franklin, D. Hasenclever, H. Tesch, M. Pfreundschuh, B. Lathan, U. Paulus, M. Sieber, J.-U. Rüffer, M. Sextro, A. Engert, J. Wolf, R. Hermann, L. Holmer, U. Stappert-Jahn, E. Winnerlein-Trump, G. Wulf, S. Krause, A. Glunz, K. von Kalle, H. Bischoff, C. Haedicke, E. Dühmke, A. Georgii, M. Loeffler and German Hodgkin's Lymphoma Study group

Department of Internal Medicine, University of Cologne Germany

Correspondence to V. Diehl Klinik I fur lnnere Medizin der Universitat zu Koln Joseph-Stelzmann-Str. 9 D-50924 Koln Germany E-mail. v.diehl{at}uni-koeln.de

The BEACOPP chemotherapy regimen for advanced Hodgkin's disease employs a rearranged schedule permitting a shortened three-week cycle. With haematological growth factor support, the dosages of cyclophosphamide, etoposide and adriamycin could be moderately escalated. The 3-armed multi-centre HD9 trial (recruitment 1993–1998; 1300 patients randomised) aimed to compare BEACOPP with the standard COPP/ABVD chemotherapy and to detect and measure the gain in efficacy, if any, due to moderate dose escalation of BEACOPP. Eight cycles were given, followed by local irradiation.

The most recent interim analysis, with 689 evaluable patients, circa 40% of all expected events and a median observation time of 27 months, showed significant differences in progression rate (P) and in two-year freedom from treatment failure (F) between the treatment arms, with escalated BEACOPP (P = 2%, F = 89%) better than baseline BEACOPP (P = 9%, F = 81%) better than COPP/ABVD (P = 13%, F = 72%). Survival was not significantly different. Acute toxicity was more severe due to dose escalation, but remained manageable.

These preliminary results suggest that BEACOPP improves efficacy. Moderate dose escalation is feasible with G-CSF support and appears likely to make a worthwhile improvement in the cure rate. The results must await confirmation (or otherwise) by the final analysis including all randomised patients and sufficiently mature data.

chemotheapy, dose escalation, efficacy, Hodgkin's disease, toxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
C. Menzel, T. Schirrmann, Z. Konthur, T. Jostock, and S. Dubel
Human antibody RNase fusion protein targeting CD30+ lymphomas
Blood, April 1, 2008; 111(7): 3830 - 3837.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. L. Kesner, W.-A. Hsueh, N. L. Htet, B. S. Pio, J. Czernin, M. D. Pegram, M. E. Phelps, and D. H.S. Silverman
Biodistribution and Predictive Value of 18F-Fluorocyclophosphamide in Mice Bearing Human Breast Cancer Xenografts
J. Nucl. Med., December 1, 2007; 48(12): 2021 - 2027.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.